O'Dorisio MS - Search Results

1

Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging.

Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL. Frühwald MC, et al. Clin Cancer Res. 2004 May 1;10(9):2997-3006. doi: 10.1158/1078-0432.ccr-03-0083. Clin Cancer Res. 2004. PMID: 15131035

2

Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors.

Khanna G, Bushnell D, O'Dorisio MS. Khanna G, et al. Oncologist. 2008 Apr;13(4):382-9. doi: 10.1634/theoncologist.2007-0175. Oncologist. 2008. PMID: 18448552 Free article. Review.

3

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.

O'Dorisio MS, Khanna G, Bushnell D. O'Dorisio MS, et al. Cancer Metastasis Rev. 2008 Dec;27(4):665-77. doi: 10.1007/s10555-008-9153-8. Cancer Metastasis Rev. 2008. PMID: 18581060 Review.

4

Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.

Khanna G, O'Dorisio MS, Menda Y, Glasier C, Deyoung B, Smith BJ, Graham M, Juweid M. Khanna G, et al. Pediatr Blood Cancer. 2008 Mar;50(3):561-6. doi: 10.1002/pbc.21194. Pediatr Blood Cancer. 2008. PMID: 17387742

5

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.

Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Menda Y, et al. J Nucl Med. 2010 Oct;51(10):1524-31. doi: 10.2967/jnumed.110.075226. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847174 Free PMC article. Clinical Trial.

6

Potential for Increasing Uptake of Radiolabeled ⁶⁸Ga-DOTATOC and ¹²³I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.

Pollard JH, Menda Y, Zamba KD, Madsen M, O'Dorisio MS, O'Dorisio T, Bushnell D. Pollard JH, et al. Among authors: o dorisio ms. Cancer Biother Radiopharm. 2021 Oct;36(8):632-641. doi: 10.1089/cbr.2020.4633. Epub 2021 Jul 12. Cancer Biother Radiopharm. 2021. PMID: 34252288 Free PMC article.

7

⁹⁰Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. Menda Y, et al. J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9. J Nucl Med. 2018. PMID: 29523629 Free PMC article. Clinical Trial.

8

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham MM, O'Dorisio TM, O'Dorisio MS. Menda Y, et al. Pancreas. 2013 Aug;42(6):937-43. doi: 10.1097/MPA.0b013e318287ce21. Pancreas. 2013. PMID: 23587853 Free PMC article.

9

Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.

Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM. Madsen MT, et al. J Nucl Med. 2006 Apr;47(4):660-7. J Nucl Med. 2006. PMID: 16595501 Free article.

10

Technical Note: Single time point dose estimate for exponential clearance.

Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS. Madsen MT, et al. Med Phys. 2018 May;45(5):2318-2324. doi: 10.1002/mp.12886. Epub 2018 Apr 16. Med Phys. 2018. PMID: 29577338 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters